Timothy Wei
Neurology · Walnut Creek, CANPI 1093762825
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,700 of the $24,167 with a category attached, or 77.4%. AbbVie accounts for 92.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $11,342 and has fallen 92.0% since, to $909 in 2025.
Across 300 payments — averaging $80.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$22K
- Teva Pharmaceuticals USA, Inc.$328
- Amgen$284
- Neurocrine Biosciences, Inc.$269
- UCB, Inc.$169
- Bausch Health US, LLC$153
- plus $736 from 14 others
Across 88 payments — averaging $326.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$19K
- Amgen$10K
What the payments were for
- Speaking & faculty fees$18,70077%
- Food & beverage$5,36822%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 217 | $22,228 |
| Teva Pharmaceuticals USA, Inc. | 13 | $328 |
| Amgen | 20 | $284 |
| Neurocrine Biosciences, Inc. | 5 | $269 |
| UCB, Inc. | 4 | $169 |
| Bausch Health US, LLC | 16 | $153 |
| Boston Scientific | 1 | $115 |
| CSL Behring | 3 | $111 |
| Johnson & Johnson | 1 | $99 |
| Pfizer | 3 | $65 |
| AstraZeneca | 2 | $63 |
| Lilly USA, LLC | 3 | $63 |
| Amneal Pharmaceuticals LLC | 4 | $57 |
| Eisai Inc. | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $18 |
| Tanabe Pharma America, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$18,700
- INGREZZA$131
- AIMOVIG$125
- Austedo XR$122
How this compares
$24,167 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 14 | $81,648 |
| RytaryCarbidopa/Levodopa | 33 | $60,706 |
| BotoxOnabotulinumtoxina | 44 | $59,390 |
| UbrelvyUbrogepant | 28 | $29,501 |
| Nurtec OdtRimegepant Sulfate | 23 | $28,668 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 14 | $19,949 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $16,701 |
| NeuproRotigotine | 13 | $10,778 |
| Zolmitriptan | 17 | $3,705 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 51 | $2,271 |
| Memantine Hcl ErMemantine Hcl | 26 | $1,935 |
| Gabapentin | 66 | $1,713 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 27 | $1,502 |
| Duloxetine Hcl | 35 | $1,491 |
| Pregabalin | 61 | $966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy | $22,228 | $88,89172 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $328 | $81,64814 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $57 | $61,29047 claims |
| PfizerNurtec Odt | $65 | $28,66823 claims |
| UCB, Inc.Neupro | $169 | $10,77813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.
Other neurology in Walnut Creek
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.